[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100621534":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":11,"responsibleParty":26,"collaborators":11,"id":30,"slug":31,"hasResults":32,"nctId":33,"briefTitle":34,"officialTitle":34,"acronym":11,"eligibilityCriteria":35,"healthyVolunteers":32,"sex":36,"minAge":37,"maxAge":38,"enrollmentInfo":39,"targetDuration":11,"studyType":42,"phases":43,"briefSummary":45,"conditions":46,"keywords":48,"overallStatus":51,"whyStopped":11,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":11},{"fullName":5,"class":6},"Anhui Provincial Cancer Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"research group","EXPERIMENTAL",null,[13],"Drug: Trifluridine\u002FTipiracil (TAS-102) combined with Apatinib",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","Trifluridine\u002FTipiracil (TAS-102) combined with Apatinib","TAS-102: 35 mg\u002Fm2\u002Fdose, taken orally within 1 hour after breakfast and dinner, twice daily, on days 1-5 of each cycle, followed by a 9-day drug-free interval, with 28 days constituting one cycle.\n\nApatinib: 500 mg\u002Fdose, once daily, administered continuously for 5 days followed by a 2-day break, with 28 days as one cycle. Imaging evaluation should be performed every 2-3 cycles until disease progression or intolerance occurs.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Yi Fu He","CONTACT","+86 13053069237","michaelhww@zju.edu.cn",{"type":27,"investigatorFullName":28,"investigatorTitle":29,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Wang Xiaojing","Chief Physician.","100621534","a-prospective-single-arm-exploratory-study-of-trifluridinetipiracil-tas-102-combined-with-apatinib-as-third-line-therapy-for-advanced-gastric-cancer-100621534",false,"NCT07371871","A Prospective, Single-arm, Exploratory Study of Trifluridine\u002FTipiracil (TAS-102) Combined With Apatinib as Third-line Therapy for Advanced Gastric Cancer","Inclusion Criteria:\n\n* Gastric cancer confirmed by histopathological or cytological diagnosis;\n* unresectable locally advanced or recurrent\u002Fmetastatic gastric cancer;\n* age 18-75 years, regardless of gender;\n* ECOG score 0-2;\n* previously received second-line treatment for advanced gastric cancer with disease progression during or after treatment;\n* at least one measurable lesion present according to RECIST 1.1 criteria;\n* laboratory tests meeting the following requirements: (1) Blood routine: HGB≥70g\u002FL; WBC≥4.0×10\\^9\u002FL; NEUT≥1.5×10\\^9\u002FL; PLT≥90×10\\^9\u002FL; (2) Blood biochemistry: ALT, AST≤2.5×upper limit of normal (ULN), serum creatinine≤1.5×upper limit of normal;\n* negative pregnancy test for patients of childbearing potential and voluntary use of effective and reliable contraception during the trial.\n\nExclusion Criteria:\n\n* Participation in other anti-tumor drug clinical trials within 4 weeks prior to enrollment;\n* Any of the following conditions that may interfere with oral medication: inability to swallow, chronic diarrhea, or intestinal obstruction;\n* Concurrent receipt of any other systemic anti-tumor therapy (excluding local treatment);\n* Previous treatment with VEGFR inhibitors (excluding ramucirumab; pan-targeted TKIs are excluded);\n* Known history of allergy to any component of the study drugs;\n* Subjects with active infectious diseases;\n* Patients deemed unsuitable for enrollment by the investigator due to potential increased study-related risks or possible interference with interpretation of study results, as assessed by the investigator.","ALL","18 Years","75 Years",{"count":40,"type":41},30,"ESTIMATED","INTERVENTIONAL",[44],"NA","To evaluate the efficacy and safety of trifluridine\u002Ftipiracil (TAS-102) combined with apatinib as third-line therapy for advanced gastric cancer",[47],"Advanced Gastric Cancer",[47,49,50],"TAS-102","Apatinib","NOT_YET_RECRUITING","2026-01-19",{"date":54,"type":55},"2026-01-28","ACTUAL",{"date":57,"type":41},"2026-01-08",{"date":59,"type":41},"2028-12-31",{"name":5,"class":6}]